Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.
Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.
“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.
No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.
The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.
Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.
Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.
Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.
Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.
Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.
Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.
Credits: X
While TrumpRx is making headlines for lowering the prices of popular weight loss drugs, something else has also grabbed attention of many. A video from the Oval Office from the Thursday Press Conference when President Donald Trump was announcing the deal with the drugmakers, a man had collapsed. Many claimed that the person who collapsed was Gordon Findlay, who is Novo Nordisk's executive. Dr Mehmet Oz, an American present and a physician was swift to check on the man who had collapsed. Independent journalist Eric Daugherty shared the video and wrote: "A man just passed out during President Trump's Oval Office announcement. Dr Oz Sprung into action and assisted him. Pray for him."
Also Read: TrumpRx: Will Trump’s New Website Make Prescription Drugs More Affordable?
The reason why many have identified the man as Gordon Findlay because in the video, David Ricks, CEO of Eli Lily could be heard asking, "You okay? Gordon, you okay?" Upon this, the White House Press Secretary Karoline Leavitt said in the statement that "a representative with one of the companies fainted". However, no names were given.
Novo Nordisk later clarified the claims, and in a statement to Newsweek, the company said, "Please be aware that CEO Mike Doustdar and EVP, US operations, Dave More were the only two Novo Nordisk representatives in the Oval Office."
Dr Oz had previously also helped out at the Oval office in April, when a child fainted while he was being sworn in. A woman, who many media outlets claimed, appeared to be Oz's daughter, Daphne, escorted the girl who had fainted. Later, the White House official confirmed to Fox News Digital that the girl was family member of Oz and had recovered.
If someone collapses in front of you, the first need is for someone to try simple CPR or cardiopulmonary resuscitation, while medical help is on its way. What must one keep in mind if someone collapses?
Check for any danger around the person, and give the shoulders of the person who collapsed a shake. Ask them if they can hear you, notes BBC.
If there is no response, tilt their head back to ensure that the airway is clear. This may be enough for the person to again start breathing.
If they are not breathing, this is when CPR becomes important.
Also Read: Trump Strikes Agreement To Cut Costs of Popular Weight Loss Drugs: All You Need to Know
As per NHS, UK, there are two correct ways to practice CPR on adults:
This is to be carry out as a chest compression
Credits: AP and Canva
Ozempic is about to go on sale! With TrumpRx, a website announced by the US President Donald Trump will allow Americans to buy popular weight loss drugs at a cheaper rate. The drugmakers Eli Lilly and Novo Nordisk have agreed to match prices to the lowest paid in peer nations for all their drugs in Medicaid and for the list prices when their medications first hit the market. They will be offering primary care medicines that will reach to customers directly at a discounted price.
While popular weight loss drugs could be bought from the website at as lowest as $149 per month, what else does TrumpRx offer?
In his own words, "By taking this bold step, we are ending the era of global price gouging at the expense of American families."
Not just Novo Nordisk and Eli Lilly, in fact, it was Pfizer, which is the first US pharmaceutical group that signed up to the website. The company said that it would offer discounts of up to 85%. This is for the medicines for those not using health insurance policies to pay and for those on the government's low-cost insurance programme - Medicaid.
The plan is to launch the website in early 2026 from where consumers could buy prescribed medicines directly from pharmaceutical companies without having to go through insurance. This is also to aid those under the Medicaid programme, which is a federal government programme for adults and children from lower-income backgrounds. The beneficiaries will have access to the drugs at a discounted prices, which is closer to those paid by national health services in foreign countries, known as the "most favoured nation" prices.
"Most Favoured Nation" or MFN prices are those that the national health services in countries including Canada, France, Germany, Italy, Japan, the United Kingdom, Switzerland and Denmark pay the US pharmaceutical companies for prescribed drugs.
Since these medicines are exported in a bulk, the prices are lowered as the purchasing power is greater to demand of the ordinary consumers. This is why pharmaceutical companies tend to sell their drugs at a lower price outside than in their own country. Earlier this year in May, Trump, thus signed an executive order that aimed at reducing prescription drug prices in the US. He stated, "The United States will no longer subsidise the health care of foreign countries.”
Apart from the lower drug prices of popular weight loss drugs, Trump, in July had sent letters to CEOs of 17 pharmaceutical companies and ordered them to reduce their prices, based on certain promises from his end, which included:
Manufacturers will be provided with an avenue to cut out middlemen and sell medicines directly to patients
Manufacturers will be supported by trade policy in raising prices internationally
Trump had also announced new 100% tariffs on imported, branded pharmaceutical products, which will allow him to deliver the second promise.
As per a 2022 study commissioned by the Office of the Assistant Secretary for Planning and Evaluation, which is published on the US government website, the standard insulin prices in the US are 10 times higher than the prices in 33 OECD countries (Organisation for Economic Cooperation and Development). Lowering of the prices of drugs domestically, and removing the middle men could bring the prices down.
The study also found that the average gross prices in US were more than 10 times the price in France, and the United Kingdom. The prices further skyrocketed by nine times in Italy, eight times the prices in Japan, seven times the prices in Germany, and more than six times in Canada.
While many people who take insulin already pay a "net price", which is lower than the standard price, however, the net price is still 2.33 times the price paid in other countries.
TrumpRx, thus, could benefit anyone who buys drugs directly from the website. This is especially for those who do not have a health insurance in the US. As per a 2024 report from the US Census Bureau, around 8%, which makes 26 million of the US population, do not have a health insurance.
Apart from Eli Lilly and Novo Nordisk's popular weight loss drugs like Zepbound, Ozempic and Wegovy, Pfizer too has shared a list of primary-care medicine, not limited to the following:
Credits: PTI
TrumpRx: US President Donald Trump had announced this week that his administration plans to roll out a new website, called TrumpRx, which will allow Americans to purchase prescription medications from pharmaceutical companies at discounted rates.
In a major step to address rising drug costs, the Trump administration also unveiled agreements with Eli Lilly and Novo Nordisk to reduce prices for popular GLP-1 medications like Ozempic, Wegovy, and Zepbound. These deals, part of the TrumpRx initiative, are expected to make the drugs more affordable for Medicare, Medicaid, and direct consumers starting in 2026.
TrumpRx is an online platform designed to let consumers buy prescription medicines directly from the manufacturers, bypassing insurance intermediaries. The website is scheduled to launch in early 2026. Users will be able to search for the specific drug they need and be directed to the drug’s manufacturer, according to USA Today. The platform will offer prices closer to what national health services pay in other countries, following the principle of “most favoured nation” pricing. Medicaid beneficiaries—federal insurance for low-income adults and children—will also have access to the platform.
Also Read: Trump Strikes Agreement To Cut Costs of Popular Weight Loss Drugs: All You Need to Know
The website is part of a broader effort by Trump to curb high prescription drug costs in the US. In July, he sent a letter to the CEOs of 17 pharmaceutical companies demanding lower prices.
In the letter, he outlined several key points:
Anyone looking to buy prescription drugs directly from manufacturers, rather than through insurance, could benefit. A 2024 US Census Bureau report noted that 8% of Americans (about 26 million people) lacked health insurance in 2023, meaning they could significantly benefit from lower prices. Medicaid may also benefit, as its deal with Pfizer offers better pricing terms. Details about how this part of the program will work are not fully clear yet. Since most Americans rely on insurance for healthcare, experts believe initial adoption of the site may be limited.
On Thursday, President Trump announced deals with Novo Nordisk and Eli Lilly to cut costs for the lowest doses of their popular weight-loss drugs, lowering barriers for new patients seeking treatment. Beyond government programs, the same GLP-1 drugs will be available directly to consumers via TrumpRx.gov, launching in January 2026.
The starting doses of injectable Wegovy and Zepbound will cost $350 per month but are expected to trend down to $245 over two years. Oral versions, including Novo Nordisk’s upcoming semaglutide pill and Eli Lilly’s orforglipron, will start at $149 per month once approved.
© 2024 Bennett, Coleman & Company Limited